Aera Therapeutics utilizes a protein nanoparticle (PNP) delivery platform that self-assembles from endogenous human proteins to package and transfer nucleic acid cargo. This technology addresses the limitations of current delivery methods for genetic medicines, enabling broader therapeutic applications.

The startup develops targeted protein degradation therapeutics that utilize novel mechanisms to modulate the degradation of disease-related proteins. This approach aims to enhance therapeutic efficacy for a range of diseases by precisely regulating protein abundance linked to disease progression.

Anaveon is developing IL-2 complexes, specifically ANV419 and ANV600, which enhance effector T cell functions to improve immune responses in cancer treatment. The company addresses the need for safe and effective immunotherapies for patients with high unmet medical needs by utilizing protein engineering to optimize cytokine activity.

Arda Therapeutics develops therapies aimed at eliminating pathogenic cells that drive chronic diseases. The company utilizes single-cell data analysis to precisely identify and characterize these target cells. This approach informs the design of specific therapies engineered to selectively eliminate only the disease-driving cell populations.

AstronauTx is developing targeted therapeutics to restore the functionality of astrocytes, which are critical for maintaining brain health. This approach aims to correct disrupted brain physiology associated with neurodegenerative diseases, potentially improving patient outcomes.

An AI-powered dating app that acts as a virtual wingwoman, using natural language processing and machine learning to facilitate personalized matchmaking and conversation starters. It addresses the challenges of initiating and maintaining connections in online dating by providing users with tailored suggestions and support, improving engagement and compatibility.

CatalYm is developing a monoclonal antibody, visugromab, that neutralizes GDF-15 to reverse immune resistance mechanisms in solid tumors, thereby enhancing anti-tumor immune responses. This approach aims to improve treatment outcomes for cancer patients who are non-responsive to existing therapies, addressing a significant gap in current immunotherapy effectiveness.

Citryll is developing CIT-013, a first-in-class monoclonal antibody that inhibits the formation of Neutrophil Extracellular Traps (NETs) and enhances their clearance, targeting a key mechanism in immune-mediated inflammatory diseases. The company focuses on treating conditions such as Rheumatoid Arthritis and Hidradenitis Suppurativa, where NETs contribute significantly to inflammation.

Develops novel inhaled therapies targeting epithelial sodium channels (ENaC) to reduce mucus congestion in respiratory diseases like cystic fibrosis, asthma, and COPD. These treatments aim to decrease lung infections and improve respiratory function, addressing the underlying causes of chronic respiratory conditions affecting over 700 million people globally.

Epsilogen develops immunoglobulin E (IgE) antibodies, specifically targeting solid tumors like ovarian cancer, to enhance treatment efficacy through improved tumor access and potency. Their lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, demonstrating safety and early signs of clinical activity in patients with folate receptor alpha positive cancers.

FoRx Therapeutics is a clinical‑stage biotech developing precision small‑molecule inhibitors that target DNA replication stress and DNA damage response pathways in treatment‑resistant cancers. Its lead program, FORX‑428, is a highly selective PARG inhibitor currently in Phase 1 trials, with additional replication‑stress‑modulating candidates advancing through lead optimization. The company leverages structure‑based design, biomarker‑driven patient selection, and oral‑bioavailable chemistry to deliver next‑generation anticancer therapeutics.

GentiBio develops a modular engineering platform that produces stable, optimized T regulatory cells (Tregs) with specific IL-2 signaling for the treatment of autoimmune and inflammatory diseases. This technology addresses the limitations of existing Treg therapeutics by enabling scalable manufacturing and targeted delivery, enhancing efficacy and safety for patients.

Granite Bio develops first-in-class therapeutic antibodies targeting the fundamental biology of inflammation, autoimmunity, and fibrosis. The company's pipeline includes assets designed to selectively deplete pathogenic cells, such as GRT-001 which targets pro-inflammatory monocytes. These novel mechanisms aim to provide efficacious treatment options where current therapies are lacking for chronic inflammatory diseases.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.

Lo provides a platform for managing and automating commercial real estate leasing workflows. It centralizes lease documentation, tracks key dates, and streamlines communication between landlords and tenants. This system helps commercial property managers reduce administrative overhead and ensure compliance across their portfolio.

NKore BioTherapeutics develops an allogeneic cellular immunotherapy platform focused on treating cancer and immune-related diseases. The company utilizes a proprietary method to activate natural killer (NK) cells, creating significantly more potent Supercharged Natural Killer (sNK) cells. This approach aims to provide a non-toxic treatment option with enhanced cytotoxicity against cancer cells, reducing the risk of tumor regeneration and metastasis.

NRG Therapeutics is a drug discovery company developing oral small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function. The company aims to slow or halt the progression of neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

This company develops therapeutics designed to enhance and protect microglia, the immune cells of the brain. Their approach utilizes generative AI and biomarker technology to address the declining debris clearance function associated with aging and neurological disease. The core value is improving brain health by restoring microglial function to clear harmful pathogens and cellular debris.

RhyGaze develops an AAV‑based gene‑therapy platform that delivers optogenetic proteins to retinal cells, restoring light sensitivity and visual signaling in patients with photoreceptor loss. The single‑dose intravitreal injection is designed for outpatient use and targets a range of inherited or acquired retinal degenerations, enabling ophthalmologists to offer functional vision improvement where existing treatments cannot restore sight.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Splice provides an integrated logistics platform that connects disparate systems for seamless data flow and automation. The platform utilizes an AI Bridge to convert unstructured documents into structured data, significantly reducing manual data handling in supply chain workflows. Key solutions include managing export schedules, automating data integration across various logistics tools, and operating container yards from a unified view.

This company develops antibody-based imaging and therapy technology to enhance cancer treatment efficacy. Their platform enables selective chemical manipulation of tagged antibodies in vivo, improving radioimmuno-imaging, therapy, and antibody-drug conjugates for more effective and lower-dose imaging.